Article thumbnail

B cell depletion reduces the development of atherosclerosis in mice

By Hafid Ait-Oufella, Olivier Herbin, Jean-David Bouaziz, Christoph J. Binder, Catherine Uyttenhove, Ludivine Laurans, Soraya Taleb, Emily Van Vré, Bruno Esposito, José Vilar, Jérôme Sirvent, Jacques Van Snick, Alain Tedgui, Thomas F. Tedder and Ziad Mallat


B cell depletion significantly reduces the burden of several immune-mediated diseases. However, B cell activation has been until now associated with a protection against atherosclerosis, suggesting that B cell–depleting therapies would enhance cardiovascular risk. We unexpectedly show that mature B cell depletion using a CD20-specific monoclonal antibody induces a significant reduction of atherosclerosis in various mouse models of the disease. This treatment preserves the production of natural and potentially protective anti–oxidized low-density lipoprotein (oxLDL) IgM autoantibodies over IgG type anti-oxLDL antibodies, and markedly reduces pathogenic T cell activation. B cell depletion diminished T cell–derived IFN-γ secretion and enhanced production of IL-17; neutralization of the latter abrogated CD20 antibody–mediated atheroprotection. These results challenge the current paradigm that B cell activation plays an overall protective role in atherogenesis and identify new antiatherogenic strategies based on B cell modulation

Topics: Brief Definitive Report
Publisher: The Rockefeller University Press
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2009). A protective function for interleukin 17A in T cell-mediated intestinal inflammation.
  2. (2000). B lymphocytes regulate dendritic cell (DC) function in vivo: increased interleukin 12 production by DCs from B cell–deficient mice results in T helper cell type 1 deviation.
  3. (2004). B-Lymphocytes in plaque and adventitia of coronary arteries in two patients with rheumatoid arthritis and coronary atherosclerosis: preliminary observations.
  4. (2003). BrdU labeling and cell analysis. BrdU labeling was performed as previously described (Fisson et al.,
  5. (2007). Cell recovery and purification, culture, proliferation, and cytokine assays. CD11c+ and CD4+ cells were purified and processed for cell proliferation assays and cytokine production as previously described in detail (Taleb et al.,
  6. (1996). Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma.
  7. (2003). Continuous activation of autoreactive CD4+ CD25+ regulatory T cells in the steady state.
  8. (2007). Defective leptin/leptin receptor signaling improves regulatory T cell immune response and protects mice from atherosclerosis.
  9. (2006). Fcgamma receptor deficiency confers protection against atherosclerosis in apolipoprotein E knockout mice.
  10. (2007). Fitness of cell-mediated immunity independent of repertoire diversity.
  11. (2004). IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis.
  12. (2002). Innate and acquired immunity in atherogenesis.
  13. (2006). Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis.
  14. (2008). Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice.
  15. (2000). Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity.
  16. (2006). Natural regulatory T cells control the development of atherosclerosis in mice.
  17. (2009). Oxidation-specific epitopes are dominant targets of innate natural antibodies in mice and humans.
  18. (2007). TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology.
  19. (2006). The immune response in atherosclerosis: a double-edged sword.
  20. (2010). The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor–dependent mechanisms during anti-CD20 antibody immunotherapy.
  21. (2005). The lamina adventitia is the major site of immune cell accumulation in standard chow-fed apolipoprotein E-deficient mice.
  22. (2005). The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice.
  23. (2009). type of autoantibodies to oxidized low-density lipoprotein has an inverse relation to carotid artery atherosclerosis.